Accession Number:



Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer

Descriptive Note:

Technical Report,22 Sep 2015,21 Sep 2016

Corporate Author:

The University of Texas MD Anderson Cancer Center Houston United States

Personal Author(s):

Report Date:


Pagination or Media Count:



The purpose of this study is to develop a strategy to identify molecular markers of response of advanced prostate cancer to specific therapies using clinically relevant prostate cancer patient-derived xenografts PDXs that are responders and nonresponders to these therapies. We will identify genomic alterations via integrative genomic analysis of these PDXs. The MD Anderson and Michigan teams will interact closely to analyze results and generate a responder ID profile hypothesis. The validity of the responder ID profiles will be assessed in clinical trials. When we were in the process of performing our studies at the MD Anderson site, we were informed that there was a miscommunication between MD Anderson and USAMRMC Animal Care and Use Review Office ACURO and that the animal protocols had not been reviewed by ACURO. Thus we were asked to stop all studies and to return all funds utilized for the project as this could not be executed until the animal protocol is approved by ACURO. In May2016, we had our animal protocol approved and we started our studies.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: